4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes

Phase 1 Completed 98 enrolled Pfizer

RandomizedSequentialDouble-blindBasic science

Summary

This is a dose-escalating study in patients with Type 2 diabetes on metformin. Participants will receive an investigational product or placebo for 28 days.

Timeline

Start: 2018-06-25
Primary completion: 2019-05-23
Completion: 2019-06-10

Publications

Saxena AR, Gorman DN, Esquejo RM, Bergman A, Chidsey K, Buckeridge C, Griffith DA, Kim AM. Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial. Nat Med. 2021 Jun;27(6):1079-1087. doi: 10.1038/s41591-021-01391-w. Epub 2021 Jun 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Danuglipron	Small molecule	15 mg	Oral
Subject	Danuglipron	Small molecule	50 mg	Oral
Subject	Danuglipron	Small molecule	150 mg	Oral
Subject	Danuglipron	Small molecule	300 mg	Oral

4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes

Summary

Timeline

Publications

Drugs

Indications